IMMUNITYBIO, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss (Deprecated 2018-01-31)
IMMUNITYBIO, INC. (IBRX) reported Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss (Deprecated 2018-01-31) of $220.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-07.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses · last filed 2018-05-07
- IMMUNITYBIO, INC. available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate loss (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $220.00K, a 35.86% decline year-over-year.
- IMMUNITYBIO, INC. available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate loss (deprecated 2018-01-31) for the quarter ending 2017-12-31 was -$54.00K.
- IMMUNITYBIO, INC. available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate loss (deprecated 2018-01-31) for the quarter ending 2017-09-30 was -$112.00K.
- IMMUNITYBIO, INC. available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate loss (deprecated 2018-01-31) for the quarter ending 2017-06-30 was -$53.00K.
- IMMUNITYBIO, INC. available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate loss (deprecated 2018-01-31) for fiscal 2016 was $418.00K, a 100.96% increase from fiscal 2015.
- IMMUNITYBIO, INC. available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate loss (deprecated 2018-01-31) for fiscal 2015 was $208.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss (Deprecated 2018-01-31) 3 month | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss (Deprecated 2018-01-31) 6 month | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss (Deprecated 2018-01-31) 9 month | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $220.00K 10-Q · filed 2018-05-07 | $166.00K derived: sum of 2 quarters · filed 2018-05-07 | $54.00K derived: sum of 3 quarters · filed 2018-05-07 | $1.00K derived: sum of 4 quarters · filed 2018-05-07 |
| 2017-12-31 | -$54.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2018-05-07 | -$166.00K derived: sum of 2 quarters · filed 2018-05-07 | -$219.00K derived: sum of 3 quarters · filed 2018-05-07 | $124.00K 10-Q · filed 2018-05-07 |
| 2017-09-30 | -$112.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$165.00K derived: sum of 2 quarters · filed 2017-11-07 | $178.00K 10-Q · filed 2017-11-07 | |
| 2017-06-30 | -$53.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $290.00K 10-Q · filed 2017-08-07 | ||
| 2017-03-31 | $343.00K 10-Q · filed 2017-05-08 | |||
| 2016-12-31 | $418.00K 10-K · filed 2018-03-12 | |||
| 2015-12-31 | $208.00K 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |